Our clients operate in dual environments—life science and business—and we have shaped our teams around the common challenges facing these segments. Valid Insight experts draw on decades of life science industry experience and business knowledge across multiple disciplines: high tier strategic consulting and scientific capabilities with data analytics, value communications, health economics, public health, real-world health outcomes research, and market access planning and execution.
BSc (Hons.), MB BChir, MRCOphth
Steve Bradshaw is Managing Director of Valid Insight. He has nearly two decades’ experience in life science consulting and healthcare. He is experienced in developing successful value-based market access strategies and solutions, including the implementation and use of real-world studies. His research interests span multiple therapy areas, with a focus on innovative medicines in the rare and orphan disease space. His career includes being Editor at Nature Clinical Reviews, Ophthalmic Surgeon UK National Health Service, and various positions to senior executive level in market access and HEOR consulting firms including Market Access Solutions LLC, Evidera and United BioSource Corporation. His education includes a first class BSc in Biochemistry, degrees in Medicine and Surgery from Gonville and Caius College, Cambridge, and a postgraduate diploma in Ophthalmology. He writes and speaks regularly on the challenges facing the global healthcare environment; he has presented widely and has over 30 publications. He is a peer reviewer for several journals, and has been quoted in publications such as BioPharm Insight, Hospital Pharmacy Europe, and Reuters.
Raf De Wilde
Raf De Wilde, is Senior Advisor at Valid Insight. He is an expert in life science market access, having over 35 years’ experience in the pharmaceutical industry and 25 years in global market access.
Raf became the head of International Marketing Services within Janssen Pharmaceutica (a Johnson & Johnson (J&J) company) in 1991, introducing Health Economics at J&J that year. Raf was Chairman of EPhMRA Primary Research and Methods Committee (1993-1995). He became VP of EPhMRA in 1994 and 1997 and President in 1995 and 1998.
In 1997, he joined Peter Lauper’s team that pioneered the ‘biosimilars’ concept and the first patient access schemes. Raf led a specialist oncology, real-world evidence and virology group between 2002 and 2004, where he created a centre of excellence for oncology pricing and specialised in biologics while leading the HEOR function at CENTOCOR. Raf was VP of Market Access at J&J leading teams working on oncology, cardiovascular and biotech products from 2004 to 2010.
Raf joined United Biosource Corporation (UBC) as Associate VP in early 2011 and stayed with Evidera until 2015. In his consulting career he has led over 100 global market access projects, including value strategies, price finding research, patient access schemes, negotiation tactics, tendering and contracting, WHO classification and naming strategies. He has moderated over 100 training workshops in Asia, Asia-Pacific, Europe, North America and Middle-East, and led the life sciences pricing training of the European Pricing Platform from 2011 to 2014.
Raf continues to teach the sessions on PROs and evidence-based medicine at the Master of Science in Pharmaceutical Medicine course of the University of Duisburg-Essen in Germany.
BA, MA, MSc, DPhil
Crispin Jenkinson is Professor of Health Services Research, Director of the Health Services Research Unit at the Nuffield Department of Population Health, and a Senior Research Fellow of Harris Manchester College at the University of Oxford. He graduated from Bedford College (University of London) before coming to Oxford where he gained an MSc in Psychology and then undertook research on the psychological impact of long-term illness for a DPhil. His main research interests include patient reported outcomes (PROs) and health status measurement, the evaluation of patient experiences of medical care, and methodology. He has extensive experience of developing and validating outcome measures and, in collaboration with others, has conducted randomised controlled trials in which such instruments have been primary end-points. This work has led to the development of several internationally recognized PRO measures including the Parkinson’s Disease Questionnaire (PDQ), Amyotrophic Lateral Sclerosis Questionnaire (ALSAQ), and the Endometriosis Health Profile (EHP). He has written and edited a number of books as well as having written over 190 peer reviewed publications.
Carole Alison Chrvala
Carole Chrvala has over 25 years’ experience as an epidemiologist, HEOR researcher and market access medical writer. Her work spans collaborations with government health agencies, payers, academic institutions, pharmaceutical and medical device companies, medical education and communication organisations, and healthcare professional societies located in the US, UK, EU, and Israel. Carole is highly experienced in epidemiologic consulting, biostatistical support, strategic competitive analysis, medical intelligence, medical writing and publication planning services in diverse therapeutic areas including oncology, cardiovascular disease, diabetes mellitus, infectious diseases, musculoskeletal disorders, neurologic disorders, pain, psychiatric disorders, rare diseases, respiratory disorders, rheumatologic disorders, and women’s health.
Carole has developed and validated risk prediction models for various chronic and infectious diseases, analysed health care resource utilisation and economic burden, determined projections for the global epidemiologic burden of diverse health conditions, developed prospective and retrospective research studies to examine the impact of clinical interventions and developed statistical analysis plans for retrospective and prospective case-control studies and randomised clinical trials.
Carole was director of Cancer Prevention and Control for the Colorado Department of Public Health and Environment (CDPHE), before setting up her own independent company. She joined the US Food and Drug Administration as a Senior Scientist and later joined the National Academies of Science as a Senior Program Officer. She has written and presented on epidemiology, health economics and outcomes research, and diverse health topics to more than 75 professional audiences and organisations.
BSc (Hons.), MRes, PhD
Dominic Jones-Phillips is a Market Access Consultant with almost a decade’s experience in consulting and industry. He has worked with a wide range of organisations, from large multinationals, to biotech start-ups, providing strategic insight and support for products throughout the lifecycle.
Dominic has worked on, and led research activities from competitor landscaping assessments to treatment pathway analysis, product profile refinement, clinical data package assessments, value message development, pricing research, price and access strategies, and payer and KOL engagement. He has extensive experience and understanding of healthcare and payer dynamics across France, Germany, Italy, Spain, Sweden and the UK, as well as Australia, Canada, the Netherlands and the US. He has led training sessions on global market access and market dynamics, has worked on and moderated multiple payer advisory boards, negotiation and value challenge workshops, as well as presenting at market access seminars and other industry events.
His career started as a research scientist for Syngenta CTL, before completing a masters and PhD and moving into consulting. He spent 5 years with Abacus International and Decision Resources Group, starting as a researcher and quickly progressing to project manager in their payer research department. In 2016 he became Director of Market Access at Apex Healthcare Consulting, where he was responsible for leading all payer research and market access strategy, prior to joining Valid Insight.
Dominic has a BSc (Hons.) in Biochemistry and Master of Research (MRes) in Functional Genomics from the University of York, and a PhD in Experimental Rheumatology from the University of Leeds.
Dip HE, MSc
James Wright is a Consultant at Valid Insight. He has twenty years’ experience in the healthcare industry, and has been involved in many pricing and access research projects. Most recently James led projects involving the development of EU patient access solutions in rare diseases and assessment of payer acceptance of limited clinical data submissions to EU agencies. He has also headed up research projects ranging from competitor landscaping and stakeholder mapping, through treatment pathway analysis and value message development, to payer and KOL engagement. James also has considerable experience in managing and running advisory boards with payers and clinical KOLs, as well as running commercial programs to develop B2B strategies.
Prior to joining Valid Insight James worked at QuintilesIMS for 13 years in Integrated Engagement Services and in Consulting Services, where he provided support and consulting in pharmaceutical market access and commercial strategy and in field based tactical delivery. James has an MSc in Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra, Barcelona, Spain.
Please use the contact form if you have any questions about our services.
152 City Road
+44 (0) 20 3750 9833